Our objective was to develop and assess a novel endogenous progenitor cell (EPC) assay based on aldehyde dehydrogenase (ALDH) activity, and to define the relationship of ALDH-bright (ALDH br ) cells with previously defined
The discovery of circulating endogenous progenitor cells (EPCs) capable of vascular repair (1) has broadened our conception of atherosclerosis pathophysiology and treatment (2) . Most studies have found an inverse correlation between EPC number and cardiac risk factors (3, 4) , disease severity (5) , and risk for future cardiovascular events (6, 7) , although these findings are not universal (8, 9) . This body of work suggests that accurate EPC enumeration may be clinically useful for assessment of vascular reparative capacity and patient risk stratification; however, EPC enumeration currently requires prompt cell culture or fluorescenceactivated cell sorting (FACS) analysis.
Cytosolic aldehyde dehydrogenase (ALDH) has been identified as the enzymatic activity responsible for the resistance of progenitor cells to chemotherapeutic agents (10) and can be used to select for a highly enriched population of progenitor cells in bone marrow (11, 12) and umbilical cord (13) sources. In addition, ALDH activity is present at high levels in progenitor precursors of a variety of mature cell lines (14 -16) and may play an important role in maintaining the progenitor cell phenotype (17) .
Recently, reagents for the dependable enumeration of aldehyde dehydrogenase-bright (ALDH br ) cells in bone marrow and mobilized blood using conventional FACS techniques and requiring only a single color channel have become available. We explored whether or not ALDH activity could be used as a novel and simpler tool to assess circulating EPC numbers in peripheral blood.
Methods
Patient enrollment and mononuclear cell isolation. Patients undergoing elective left heart catheterization were ap-proached for consent, and after arterial sheath insertion 30-ml peripheral blood was removed and stored in ethylenediaminetetraacetic acid tubes. Arterial blood was subjected to centrifugation (2,000 g ϫ 10 min), and the buffy coat was treated with 10 volumes of erythrocyte lysis buffer (Aldagen, Durham, North Carolina). The mononuclear cells (MNCs) were isolated by centrifugation (250 g ϫ 5 min), washed with phosphate-buffered saline-1% bovine serum albumin (Invitrogen, Carlsbad, California), and aliquoted for analysis. Enumeration of ALDH br cells. Mononuclear cells (2 ϫ 10 6 ) were aliquoted to an Aldecount tube (Aldagen Inc., Durham, North Carolina), incubated with BODIPY-AAD at 37°C for 30 min, and maintained on ice to retain the fluorescent byproduct. A control reaction was performed in the presence of diethylaminobenzaldehyde. Cells were spun at 250 g ϫ 5 min, the reaction buffer removed, and the cells suspended in assay buffer on ice until FACS analysis was performed.
Analysis of EPCs based on cell surface marker expression.
Mononuclear cells (4 ϫ 10 6 cells) were aliquoted, incubated with Fc receptor (FcR) blocking reagent (Miltenyi Biotec, Auburn, California) for 10 min, and incubated with CD133-APC (Miltenyi Biotec), CD34-FITC (Miltenyi Biotec), and VEGFR-2-PE (R&D Systems, Minneapolis, Minnesota) for 60 min at 4°C. Dead and dying cells were excluded using staining with 7-AAD (1 g/10 6 cells; Invitrogen). Directly conjugated isotype control antibodies were used to set baseline fluorescence levels. FACS analysis. Flow cytometry was performed by trained technicians blinded to patient identity using an LSR II flow cytometer (BD Biosciences, San Jose, California) and analyzed using FlowJo software (Treestar, Costa Mesa, California). Compensation was performed daily using BD CompBeads incubated with each antibody.
Analysis was performed by gating lymphocytes and monocytes on the basis of light-scattering properties. The EPCs were expressed as a percentage of this monocyte/ lymphocyte gate. Expansion of ALDH br cells into endothelial cells. Bone marrow was purchased from Cambrex (Walkersville, Maryland), depleted of erythrocytes using erythrocyte lysis buffer, labeled with Aldefluor reagent according to the manufacturer's directions, and sorted on a modified FACS-ARIA cell sorter (BD Biosciences) at 4°C.
The CD133/CD34 selection was performed using CD133-MACS beads (Miltenyi Biochemical). After elution from the beads, cells were incubated with PE-conjugated anti-CD34 and sorted on a modified FACS-ARIA cell sorter. The EPCs (5,000) were plated into fibronectincoated 4-well chamber slides (BD Biosciences) and incubated in M199 medium containing 20% fetal calf serum, 10 ng/ml recombinant human vascular endothelial growth factor, 1 ng/ml b-fibroblast growth factor, and 2 ng/ml insulin-like growth factor 1. The numbers of adherent elliptical endothelial cells were quantitated after 5 days. The averages of 10 experiments are shown. Duke Cardiovascular Databank. The methods of the Duke Cardiovascular Databank have been previously described (18, 19) . In brief, all patients who have undergone cardiac catheterization, percutaneous coronary intervention, or cardiac surgery have had their demographic, clinical, angiographic, and procedural data entered into a standard database. All cardiac catheterization procedures are systematically reviewed in a standardized fashion by 2 operators. Coronary disease severity was summarized as number of diseased coronary vessels, defined by at least 1 narrowing Ն75%. Statistical analysis. The median and mean numbers (with standard deviations [SD]) of EPCs determined using each assay are reported, as are the mean numbers (ϮSD) of ALDH br cells expressing specific cell surface markers. A Pearson correlation coefficient between independent EPC assessments was determined to assess the precision and temporal stability of EPC assays. To compare these correlations, the absolute difference between each matched pair of determinations was calculated and these differences compared using a Mann-Whitney test.
A D'Agostino and Pearson omnibus normality test was used to determine the normality of each distribution. Given non-normal distributions, Spearman correlations are reported for associations between EPC types as well as the association of ALDH br cells with age. Analysis of variance and analysis for linear trend were performed to assess association of ALDH br cells with extent of coronary artery disease (CAD).
GraphPad Prism 4.0 (GraftPad Software, San Diego, California) was used for all analyses.
Results

ALDH assay and characterization of ALDH
br cells. Analysis of ALDH activity was readily performed and resulted in the straightforward identification of cells characterized by high levels of ALDH activity and low sidescatter ( Fig. 1 ). This population is not observed in the presence of diethylaminobenzaldehyde, a potent inhibitor of ALDH.
We characterized ALDH br cells by counterstaining for CD133, CD34, and vascular endothelial growth factor receptor (VEGFR)-2 expression in 21 patients. As shown in Figure 2 
014%]).
Correlation among EPC assay methodologies. We determined the association of ALDH br cells with EPCs identified based on expression of CD133, CD34, and VEGFR-2. We observed a strong correlation between EPC cell numbers identified using the ALDH assay relative to those enumerated based on expression of CD133, CD34, and CD133/ CD34 (r ϭ 0.25, 0.55, and 0.72, respectively) (Figs. 3A to  3C ). In contrast, ALDH br cell numbers failed to correlate with the numbers of cells expressing VEGFR-2 or VEGFR-2 and CD34, commonly used markers for EPC determination (Fig 3D) . Correlation between ALDH assay findings and patient age and CAD severity. To assess the relationship between chronic vascular injury and ALDH br cells, we examined the association between the numbers of ALDH br cells and patient age and extent of CAD. As shown in Figure 4 , the numbers of ALDH br cells varied inversely with patient age (p Ͻ 0.005). Patients were then divided into those with normal or minimal disease with no significantly obstructed vessels, singlevessel disease, and advanced multivessel CAD (Fig 4) . We found a stepwise depletion of ALDH br cells in patients directly related to the extent of CAD.
Discussion
Since the initial description of endogenous circulating progenitor cells capable of vascular repair (1), the number of published reports identifying and enumerating these cells Patient Characteristics 
has dramatically escalated. The use of EPC levels to predict cardiac risk has been explored in 2 reports demonstrating a relationship between EPC numbers and subsequent clinical outcomes (6, 7) , suggesting that EPC enumeration may be clinically useful for patient risk stratification; however, the methodologies required for EPC enumeration require proficiency with cell culture or complex FACS analysis using multiple cell surface markers. Aldehyde dehydrogenase is a key enzymatic activity expressed at high levels in progenitor cells. Not only may ALDH activity be a fundamental property of the progenitor cell phenotype (17) , but also selection on the basis of ALDH level may identify cells with greater proliferative and reparative capacity than progenitor cells selected on the basis of other markers (12, 20) . In addition, ALDH br cells are capable of differentiation into a variety of phenotypes (15, 16 ϩ VEGFR-2 ϩ EPCs, identify a distinct progenitor cell population. Indeed, evidence suggests that different but widely published EPC assays identify cell types which fail to correlate with one another and likely represent distinct populations (21, 22) . Because ALDH activity selects for an early progenitor cell phenotype, and because VEGFR-2 is a marker of mature endothelial cells, the numbers of ALDH br cells may more accurately reflect the levels of progenitors capable of long-term selfreplication (11) .
We found a close correlation between the frequency of ALDH br cells and patients' age and a stepwise association with CAD severity. These observations suggest that ALDH br cell depletion due to a combination of time and chronic vascular injury may play an important role in the loss of vascular reparative capacity preceding the development of clinically apparent vascular disease.
The identity of circulating ALDH br cells and their ability to contribute to vascular repair is at present not completely known; however, several lines of evidence point to the importance of these cells in vascular health. First, we have shown that bone marrow ALDH br cells are readily cultured into cells expressing multiple endothelial markers and show a greater capability for endothelial cell reconstitution than EPCs identified on the basis of CD133 and CD34 expression, findings recently corroborated by the demonstration that the ALDH br population of bone marrow cells is markedly enriched in EPCs (23) . Although bone marrow and unmobilized circulating progenitors may differ, significant evidence suggests that ALDH br cells from a variety of sources, including marrow, umbilical cord blood, and mobilized blood, is highly concentrated in progenitor cells of multiple phenotypes, including endothelial cells (13, 16, 23, 24) . Second, the correlation of ALDH br cells with CD133 ϩ CD34 ϩ cells and the high levels of crossexpression of CD34 and CD133 in the ALDH br cell population suggest that the ALDH assay identifies a population that contains within it a high proportion of cells previously identified as EPCs. Finally, the correlation of ALDH br cells with extent of vascular disease suggests that ALDH activity identifies cells which play an important role in maintaining vascular integrity.
Whether or not enumeration of ALDH br cells in patients more accurately assesses reparative capacity and risk for future cardiovascular events awaits further validation. Ulti- Povsic et al. December 4, 2007 December 4, :2243 Identification of EPCs Based on ALDH Activity mately, the utility of enumerating ALDH br EPCs will depend on the association of these cells with clinical outcomes; however, the simplicity and reliability of this technique might allow extension of EPC analysis to a wider range of clinical settings, expanding the contexts in which EPC biology might be explored.
Conclusions
The measurement of ALDH activity in blood MNCs is a promising technique for the accurate, reproducible enumeration of circulating EPCs. Aldehyde dehydrogenase-bright cells can be enumerated with greater simplicity than other EPC types, correlate strongly with some, but not all, previously identified EPCs, and are depleted in elderly patients with coronary disease.
The degree to which enumeration of ALDH br progenitor cells reflects reparative capacity, as well as the association of ALDH br cells with clinical outcomes, will define the usefulness of enumerating these cells for risk stratification of patients as well as further define the value of such cells for treatment of vascular disease.
